269 related articles for article (PubMed ID: 20535005)
1. Hepatic fibrosis and the renin-angiotensin system.
Abbas G; Silveira MG; Lindor KD
Am J Ther; 2011 Nov; 18(6):e202-8. PubMed ID: 20535005
[TBL] [Abstract][Full Text] [Related]
2. The role of the renin-angiotensin system in liver fibrosis.
Munshi MK; Uddin MN; Glaser SS
Exp Biol Med (Maywood); 2011 May; 236(5):557-66. PubMed ID: 21508249
[TBL] [Abstract][Full Text] [Related]
3. Liver fibrosis: a balance of ACEs?
Warner FJ; Lubel JS; McCaughan GW; Angus PW
Clin Sci (Lond); 2007 Aug; 113(3):109-18. PubMed ID: 17600527
[TBL] [Abstract][Full Text] [Related]
4. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
Grace JA; Herath CB; Mak KY; Burrell LM; Angus PW
Clin Sci (Lond); 2012 Aug; 123(4):225-39. PubMed ID: 22548407
[TBL] [Abstract][Full Text] [Related]
5. Cytokines and renin-angiotensin system signaling in hepatic fibrosis.
Moreno M; Bataller R
Clin Liver Dis; 2008 Nov; 12(4):825-52, ix. PubMed ID: 18984469
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of angiotensin-converting enzyme (ACE) 2 in hepatic fibrosis by ACE inhibitors.
Huang ML; Li X; Meng Y; Xiao B; Ma Q; Ying SS; Wu PS; Zhang ZS
Clin Exp Pharmacol Physiol; 2010 Jan; 37(1):e1-6. PubMed ID: 19793108
[TBL] [Abstract][Full Text] [Related]
7. Blockade of renin-angiotensin system in antifibrotic therapy.
Yoshiji H; Kuriyama S; Fukui H
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S93-5. PubMed ID: 17567477
[TBL] [Abstract][Full Text] [Related]
8. The comparative efficacy of renin-angiotensin system blockers in schistosomal hepatic fibrosis.
Parreira NA; Ramalho FS; Augusto MJ; Silva DM; Prado CM; Elias Júnior J; Rodrigues V; Ramalho LNZ
Exp Parasitol; 2018 Aug; 191():9-18. PubMed ID: 29890165
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme 2 and AMPK/mTOR pathway in the treatment of liver fibrosis: Should we consider further implications?
Barone M
World J Gastroenterol; 2024 May; 30(18):2391-2396. PubMed ID: 38764773
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.
Goh GB; Pagadala MR; Dasarathy J; Unalp-Arida A; Sargent R; Hawkins C; Sourianarayanane A; Khiyami A; Yerian L; Pai R; McCullough AJ; Dasarathy S
Liver Int; 2015 Mar; 35(3):979-85. PubMed ID: 24905085
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases.
Yoshiji H; Noguchi R; Ikenaka Y; Kitade M; Kaji K; Tsujimoto T; Uemura M; Fukui H
Curr Med Chem; 2007; 14(26):2749-54. PubMed ID: 18045121
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review.
Kim G; Kim J; Lim YL; Kim MY; Baik SK
Hepatol Int; 2016 Sep; 10(5):819-28. PubMed ID: 26903052
[TBL] [Abstract][Full Text] [Related]
13. Blockade of the renin-angiotensin system improves the early stages of liver regeneration and liver function.
Koh SL; Ager E; Malcontenti-Wilson C; Muralidharan V; Christophi C
J Surg Res; 2013 Jan; 179(1):66-71. PubMed ID: 23110972
[TBL] [Abstract][Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
15. [What have we learned from converting enzyme inhibitors on renin-angiotensin system?].
Waeber B; Nussberger J; Brunner HR
Rev Prat; 1992 Dec; 42(20):2529-32. PubMed ID: 1338608
[TBL] [Abstract][Full Text] [Related]
16. Effects of perindopril and valsartan on expression of transforming growth factor-beta-Smads in experimental hepatic fibrosis in rats.
Xu W; Song S; Huang Y; Gong Z
J Gastroenterol Hepatol; 2006 Aug; 21(8):1250-6. PubMed ID: 16872305
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor.
Yoshiji H; Kuriyama S; Fukui H
Tumour Biol; 2002; 23(6):348-56. PubMed ID: 12677092
[TBL] [Abstract][Full Text] [Related]
18. [Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
Sanada S; Kitakaze M
Nihon Rinsho; 2003 May; 61(5):821-6. PubMed ID: 12755009
[TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation and atrial fibrosis.
Tan AY; Zimetbaum P
J Cardiovasc Pharmacol; 2011 Jun; 57(6):625-9. PubMed ID: 21633248
[TBL] [Abstract][Full Text] [Related]
20. [The renin-angiotensin-aldosterone system, angiotensin I converting enzyme, and the ACE-inhibitors. Historical perspective and recent findings].
Gensini GF; Lippi D; Conti AA
Recenti Prog Med; 2002 Oct; 93(10):544-53. PubMed ID: 12405014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
